Pharmacophore There must be a specific binding site in the drug-forming target that binds to the drug. Compounds that are active against a target must have similar structural features. The most common shared property of these compounds is defined as pharmacophores. The significance of the pharmacophore model The… Continue Reading RDKit: Visual Pharmacophore
Alzheimer’s disease, commonly known as Alzheimer’s disease, is a neurodegenerative disease. Patients may experience memory loss, language problems, slow response, lost, mental behavior, etc., and even worse, they will not know their loved ones. According to the data, 50 million people in the world suffer from Alzheimer’s disease in… Continue Reading Is the vaccine returning to the development of new drug development for Alzheimer’s disease?
In order to support its uncontrolled growth, tumors devour large amounts of nutrients. For decades, scientists have been trying to develop drugs that cut off the “food” supply of tumors. On November 7, a recent study published in the journal Science, the team from the Johns Hopkins Cancer… Continue Reading Science: Greatly improve the efficacy of PD-1, new anticancer drugs will start human trial next year
Mutations in the oncoprotein KRAS occur in about 25% of cancer cases and are associated with poor prognosis of the disease. Therefore, scientists believe that blocking KRAS signaling is a potential anti-cancer pathway. However, previous decades of research have shown that this protein may be a “non-medicinal” target because… Continue Reading Nature: KRAS drugs enter the “outbreak period”, 5 products carry out human trials
On November 7, Arkuda Therapeutics announced the completion of a $44 million Series A round of financing, led by Atlas Venture and Pfizer Ventures, and Tekla Capital Management and BioInnovation Capital. The company will use the funds to promote its treatment of frontotemporal dementia (FTD) drugs through Phase I… Continue Reading Targeting granule protein precursors to prevent dementia, this company is spotlighted by Pfizer